Endocrinol Metab.  2023 Apr;38(2):223-225. 10.3803/EnM.2023.201.

Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy

• Cho EH

• KMID: 2541878
• DOI: http://doi.org/10.3803/EnM.2023.201

Reference

1. Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol. 2020; 42:669–80.

2. Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev. 2013; 12:629–32.

3. Oh TK, Song IA. Trends in long-term glucocorticoid use and risk of 5-year mortality: a historical cohort study in South Korea. Endocrine. 2020; 69:634–41.

4. Einarsdottir MJ, Ekman P, Molin M, Trimpou P, Olsson DS, Johannsson G, et al. High mortality rate in oral glucocorticoid users: a population-based matched cohort study. Front Endocrinol (Lausanne). 2022; 13:918356.

5. Strehl C, Buttgereit F. Long-term glucocorticoid therapy: is there a safe dosage? Internist (Berl). 2016; 57:934–9.

6. Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016; 75:952–7.

7. del Rincon I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66:264–72.

8. Boers M, Pincus T. Long-term glucocorticoid use in rheumatoid arthritis. J Rheumatol. 2021; 48:1342.

9. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009; 160:719–29.

10. Ku EJ, Song KH, Kim KM, Seo GH, Yoo SJ. Mortality and severity of coronavirus disease 2019 in patients with long-term glucocorticoid therapy: a Korean nationwide cohort study. Endocrinol Metab (Seoul). 2023; 38:253–9.

11. Ward D, Gortz S, Thomson Ernst M, Andersen NN, Kjaer SK, Hallas J, et al. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J. 2022; 59:2100769.

12. Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, et al. Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21:1063.

13. Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021; 223:23–7.

14. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020; 324:1307–16.

15. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324:1330–41.